Venture Capital Information
Alumni of the University of Toronto's 021 Entrepreneurs Group, working across various industries, often extend project opportunities or job referrals. Members who are interested have the chance to directly communicate with the respective companies and become involved in the fundraising process.
Historical Investment Cases
01. A targeted macromolecular innovative drug development project
CAxxxx represents a groundbreaking humanized antibody engineered to address the deficiency of platelet glycoprotein Ibα. Within its product range, CAxxxx has introduced a monovalent antibody under the same name. Distinguishing itself from other drugs, CAxxxx exhibits multifaceted capabilities, effectively inhibiting platelet activation and aggregation. This action, in turn, minimizes the development of blood clots and averts vascular blockages. Additionally, CAxxxx can mitigate platelet interactions with tumor cells, reducing the risk of tumor metastasis.
The mechanism of action primarily focuses on the following aspects: Firstly, it selectively inhibits vascular blockage under conditions of high blood flow shear stress, particularly at critical moments when blood vessels are on the verge of closure or undergoing intermittent blockage and reperfusion. Secondly, it can suppress platelet-mediated inflammatory responses, such as the interaction between platelets and neutrophils. Lastly, CAxxxx also enhances cerebral blood flow in ischemic regions and reduces the severity of neural function deficits.
In the realm of clinical applications, CAxxxx's scope extends across various domains. It can be used in conjunction with intravenous thrombolytic drugs such as t-PA and urokinase. It's also applicable for endovascular interventions, including mechanical thrombectomy, arterial thrombolysis, and stent placement. Furthermore, it can serve as an option for perioperative intravenous administration or combined intracatheter delivery. For patients beyond the treatment time window, those with lacunar stroke or other cryptogenic causes of ischemic stroke, CAxxxx can also stand as an independent therapeutic choice.
According to the perspective of the University of Toronto 021 Entrepreneurs Group Alumni Foundation general partner, there are currently no drugs targeting the same pathway available on the market. Therefore, CAxxxx can be seen as a pioneering novel drug for this target, possessing potential competitive advantages in the market.
Data from the Ellen MacArthur Foundation reveals that the fashion industry is responsible for roughly 10% of the world's carbon emissions, exceeding the total carbon emissions of both the aviation and maritime sectors combined. Recycling and reusing 1 kilogram of clothing can lead to a reduction of 3.6 kilograms of carbon dioxide emissions, along with saving 6,000 liters of water, 0.3 kilograms of fertilizers, and 0.2 kilograms of pesticides. The Company has harnessed the advantages of its in-house factories to make clothing recycling and reuse a reality, aligning with national policies and future development trends.
The company is based on the construction of a 5G smart care central factory for "new city infrastructure support," utilizing the C2F model to innovate in the realm of comprehensive household care. Through the gateway of care, it achieves intelligent home services. It has already established 53 standardized smart central care factories in China, covering a population of over 400 million people.
According to the perspective of the University of Toronto 021 Entrepreneurs Group Alumni Foundation general partner, the concentration in the care industry is quite low, and there's a significant gap in the market for a nationally standardized health care enterprise, offering substantial opportunities for consolidation.
